Track CTMX and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Create a free account to build watchlists, compare peers, and value any stock.
No credit card required
CTMX - CytomX Therapeutics Inc (CTMX) has a revenue of $35.54M, down 44.8% over the past year and up 2.2% per year over the past five years.
Revenue TTM
$35.54M
5Y CAGR
2.18%
3Y CAGR
12.75%
Gross Margin
97.86%
| Year | Revenue | Change |
|---|---|---|
| 2025 | $76.20M | -44.82% |
| 2024 | $138.10M | +36.45% |
| 2023 | $101.21M | +90.38% |
| 2022 | $53.16M | -23.59% |
| 2021 | $69.57M | -30.68% |
| 2020 | $100.36M | +74.58% |
| 2019 | $57.49M | -3.38% |
| 2018 | $59.50M | -16.92% |
| 2017 | $71.62M | - |
| Quarter | Revenue | Change |
|---|---|---|
| Q1 2026 | $10.26M | +1447.21% |
| Q4 2025 | $663.00K | -88.88% |
| Q3 2025 | $5.96M | -68.04% |
| Q2 2025 | $18.66M | -63.36% |
| Q1 2025 | $50.92M | +33.66% |
| Q4 2024 | $38.09M | +13.94% |
| Q3 2024 | $33.43M | +33.12% |
| Q2 2024 | $25.11M | -39.43% |
| Q1 2024 | $41.46M | +55.83% |
| Q4 2023 | $26.61M | +0.85% |
| Q3 2023 | $26.38M | +6.71% |
| Q2 2023 | $24.72M | +5.21% |
| Q1 2023 | $23.50M | +16.78% |
| Q4 2022 | $20.12M | +80.52% |
| Q3 2022 | $11.15M | -13.27% |
| Q2 2022 | $12.85M | +42.18% |
| Q1 2022 | $9.04M | -54.17% |
| Q4 2021 | $19.73M | +12.17% |
| Q3 2021 | $17.59M | +7.98% |
| Q2 2021 | $16.29M | +1.98% |
| Q1 2021 | $15.97M | -2.46% |
| Q4 2020 | $16.37M | -7.95% |
| Q3 2020 | $17.79M | +7.11% |
| Q2 2020 | $16.61M | -66.51% |
| Q1 2020 | $49.59M | +499.02% |
| Q4 2019 | $8.28M | -22.71% |
| Q3 2019 | $10.71M | +18.85% |
| Q2 2019 | $9.01M | -69.43% |
| Q1 2019 | $29.48M | +157.04% |
| Q4 2018 | $11.47M | -8.30% |
| Q3 2018 | $12.51M | -41.38% |
| Q2 2018 | $21.34M | +50.44% |
| Q1 2018 | $14.18M | -47.61% |
| Q4 2017 | $27.07M | +12.13% |
| Q3 2017 | $24.14M | +175.87% |
| Q2 2017 | $8.75M | -24.89% |
| Q1 2017 | $11.65M | +85.79% |
| Q4 2016 | $6.27M | +81.59% |
| Q3 2016 | $3.45M | +11.64% |
| Q2 2016 | $3.09M | - |
Revenue — often called the top line — is the total amount a company earns from selling its products and services before any expenses are deducted. Consistent revenue growth is a core signal of expanding demand and a healthy business.